Table 1.
Baseline Characteristics
| Characteristic | Patients (N = 25) |
|---|---|
| Age, y | |
| Median (range) | 61 (47–69) |
| Sex, n (%) | |
| Male | 19 (76.0) |
| Female | 6 (24.0) |
| ECOG performance status, n (%) | |
| 0 | 5 (20.0) |
| 1 | 20 (80.0) |
| History of smoking, n (%) | |
| Never smoked | 6 (24.0) |
| Current or former smoker | 19 (76.0) |
| Histologic type, n (%) | |
| Adenocarcinoma | 23 (92.0) |
| Large cell carcinoma | 1 (4.0) |
| Others | 1 (4.0) |
| Disease stage, n (%) | |
| IIIB-C | 3 (12.0) |
| IV | 21 (84.0) |
| Unknown | 1 (4.0) |
| No. of organs with metastasis, n (%) | |
| 0 | 4 (16.0) |
| 1-2 | 16 (64.0) |
| >2 | 5 (20.0) |
| Median bTMB (range), muts/Mba | 3.08 (1.54–13.33) |
| PD-L1 TPS, n (%) | |
| <1% | 10 (40.0) |
| ≥1% | 15 (60.0) |
| ≥50% | 4 (16.0) |
bTMB, blood tumor mutational burden; ECOG, Eastern Cooperative Oncology Group; muts/Mb, mutations per megabase; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; TPS, tumor proportion score.
a
Tissue TMB was assessed in six patients, with a median of 3.08 muts/Mb (range: 1.03–6.15).